109 related articles for article (PubMed ID: 36807440)
21. Mesenchymal stem cells induce PD-L1 expression through the secretion of CCL5 in breast cancer cells.
Aboulkheyr Es H; Bigdeli B; Zhand S; Aref AR; Thiery JP; Warkiani ME
J Cell Physiol; 2021 May; 236(5):3918-3928. PubMed ID: 33145762
[TBL] [Abstract][Full Text] [Related]
22. DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Sasidharan Nair V; El Salhat H; Taha RZ; John A; Ali BR; Elkord E
Clin Epigenetics; 2018; 10():78. PubMed ID: 29983831
[TBL] [Abstract][Full Text] [Related]
23. TSG-6 in conditioned media from adipose mesenchymal stem cells protects against visual deficits in mild traumatic brain injury model through neurovascular modulation.
Jha KA; Pentecost M; Lenin R; Gentry J; Klaic L; Del Mar N; Reiner A; Yang CH; Pfeffer LM; Sohl N; Gangaraju R
Stem Cell Res Ther; 2019 Nov; 10(1):318. PubMed ID: 31690344
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1.
Azarbarzin S; Hosseinpour-Feizi MA; Banan Khojasteh SM; Baradaran B; Safaralizadeh R
Life Sci; 2021 Feb; 267():118939. PubMed ID: 33359245
[TBL] [Abstract][Full Text] [Related]
25. Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer.
Mu L; Yu W; Su H; Lin Y; Sui W; Yu X; Qin C
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1036-1042. PubMed ID: 30983436
[TBL] [Abstract][Full Text] [Related]
26. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.
Wang X; Yang L; Huang F; Zhang Q; Liu S; Ma L; You Z
Immunol Lett; 2017 Apr; 184():7-14. PubMed ID: 28223102
[TBL] [Abstract][Full Text] [Related]
27. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
28. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
30. Mesenchymal stem cells protect renal tubular cells via TSG-6 regulating macrophage function and phenotype switching.
Zhao Y; Zhu XY; Song T; Zhang L; Eirin A; Conley S; Tang H; Saadiq I; Jordan K; Lerman A; Lerman LO
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F454-F463. PubMed ID: 33554782
[TBL] [Abstract][Full Text] [Related]
31. TSG-6 promotes Cancer Cell aggressiveness in a CD44-Dependent Manner and Reprograms Normal Fibroblasts to create a Pro-metastatic Microenvironment in Colorectal Cancer.
Liu B; Liu T; Liu Y; Feng X; Jiang X; Long J; Ye S; Chen D; Wang J; Yang Z
Int J Biol Sci; 2022; 18(4):1677-1694. PubMed ID: 35280699
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A
Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367
[TBL] [Abstract][Full Text] [Related]
34. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
35. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
36. PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma.
Stevenson VB; Perry SN; Todd M; Huckle WR; LeRoith T
Vet Pathol; 2021 Jul; 58(4):692-698. PubMed ID: 34169800
[TBL] [Abstract][Full Text] [Related]
37. Immune regulation of canine tumour and macrophage PD-L1 expression.
Hartley G; Faulhaber E; Caldwell A; Coy J; Kurihara J; Guth A; Regan D; Dow S
Vet Comp Oncol; 2017 Jun; 15(2):534-549. PubMed ID: 26842912
[TBL] [Abstract][Full Text] [Related]
38. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
[No Abstract] [Full Text] [Related]
39. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
